Bemcentinib (Standard)

• Description:

  Bemcentinib (Standard) is the analytical standard of Bemcentinib. This product is intended for research and analytical applications. Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer[1][2].

• UNSPSC:

  12352100

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Reference Standards; TAM Receptor

• Related Pathways:

  Others; Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Purity:

  97.51

• Smiles:

  NC1=NC(NC2=CC(CC[C@@H](N3CCCC3)CC4)=C4C=C2)=NN1C(N=N5)=CC6=C5C7=CC=CC=C7CCC6

• Molecular Formula:

  C30H34N8

• Molecular Weight:

  506.64

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011 Dec;131 (12) :2448-57.|[2]Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010 Feb 15;70 (4) :1544-54.|[3]Lijnen HR, et al. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011 May;337 (2) :457-64.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, sealed storage, away from light and moisture

• Scientific Category:

  Reference Standards

• Clinical Information:

  No Development Reported

• CAS Number:

  [1037624-75-1]